Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO®
TIBSOVO® received approval to become the first and only therapy approved for newly diagnosed AML patients with an IDH1 mutation who are ineligible for Intensive Chemotherapy. ¹ With this most recent press release the approval, the stock has increased over 5%. This news may be the catalyst to support Agios in reversing their downtrend. I will be keeping a close eye on this ticker in hopes of confirming a reversal. Continue to follow my blog for a technical analysis of AGIO .
For the original post, please click the following link:
- Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy.; (2019). Available at